Proteon Therapeutics

Enanta Pharmaceuticals Announces the Appointment of Matthew P. Kowalsky as Chief Legal Officer

Retrieved on: 
Tuesday, April 30, 2024
Professional Services, Health, Infectious Diseases, Legal, Clinical Trials, Pharmaceutical, Biotechnology, Corporation, University, General counsel, Eli Lilly, ARIAD Pharmaceuticals, Virology, Hall, Civil Service (United Kingdom), B.A, Patient, Acquisition, White, Caregiver, Proteon Therapeutics, Multimedia, Intellectual property, Notre Dame Law School, Medication, Therapy, Cubist Pharmaceuticals, Growth, Pharmaceutical industry

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced the appointment of Matthew P. Kowalsky, J.D., as Chief Legal Officer.

Key Points: 
  • Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced the appointment of Matthew P. Kowalsky, J.D., as Chief Legal Officer.
  • In this role, he will lead all legal and compliance activities for Enanta, as well as provide strategic guidance and corporate governance oversight.
  • Prior to joining Enanta, Mr. Kowalsky held legal and operational roles of increasing responsibility at Sigilon Therapeutics, Inc., until its acquisition by Eli Lilly in 2023.
  • Most recently, he served as the Chief of Staff and Chief Legal and Administrative Officer of Sigilon, which he joined in 2019 as its General Counsel and Corporate Secretary.

Abzena Partners with ProteoNic to Offer Enhanced CHO Cell Line Platform for Complex Biologics

Retrieved on: 
Wednesday, December 6, 2023
Unic, Patient, SAN, Proteon Therapeutics, Partnership, CHO, CDMO, Immortalised cell line, Fine chemical

SAN DIEGO, Dec. 6, 2023 /PRNewswire/ -- Abzena, the leading end-to-end bioconjugate and complex biologics CDMO has announced a partnership with ProteoNic Biosciences BV, to license their premium protein expression technology, 2G UNic®. This state-of-the-art vector technology will significantly improve the production of high-yielding CHO cell lines for Abzena's customers.

Key Points: 
  • This state-of-the-art vector technology will significantly improve the production of high-yielding CHO cell lines for Abzena's customers.
  • For the past 20 years, Abzena has built a strong reputation for producing high-yielding mammalian cell lines for protein targets.
  • Frank Pieper, CEO of ProteoNic commented: "We are pleased that we can contribute to achieving the best results for Abzena and its customers.
  • Under the agreement, Abzena gains worldwide, non-exclusive commercial rights for the application of ProteoNic's 2G UNic® premium vector technology in the development of high-yielding CHO cell lines.

Abzena Partners with ProteoNic to Offer Enhanced CHO Cell Line Platform for Complex Biologics

Retrieved on: 
Wednesday, December 6, 2023
Unic, Patient, SAN, Proteon Therapeutics, Partnership, CHO, CDMO, Immortalised cell line, Fine chemical

SAN DIEGO, Dec. 6, 2023 /PRNewswire/ -- Abzena, the leading end-to-end bioconjugate and complex biologics CDMO has announced a partnership with ProteoNic Biosciences BV, to license their premium protein expression technology, 2G UNic®. This state-of-the-art vector technology will significantly improve the production of high-yielding CHO cell lines for Abzena's customers.

Key Points: 
  • This state-of-the-art vector technology will significantly improve the production of high-yielding CHO cell lines for Abzena's customers.
  • For the past 20 years, Abzena has built a strong reputation for producing high-yielding mammalian cell lines for protein targets.
  • Frank Pieper, CEO of ProteoNic commented: "We are pleased that we can contribute to achieving the best results for Abzena and its customers.
  • Under the agreement, Abzena gains worldwide, non-exclusive commercial rights for the application of ProteoNic's 2G UNic® premium vector technology in the development of high-yielding CHO cell lines.

NecstGen and ProteoNic report development of improved viral vectors through the application of premium 2G UNic™ technology

Retrieved on: 
Tuesday, September 19, 2023
Tissue, LV, Center for Cell and Gene Therapy, Gene, Leiden Bio Science Park, Proteon Therapeutics, AAV, CDMO, Patient, Cell, Vaccine

LEIDEN, the Netherlands, Sept. 19, 2023 /PRNewswire/ -- Necstgen, a non-profit CDMO and ProteoNic, a leading provider of premium vector technology and services for efficient production of biologics, announce the successful development of improved lentiviral (LV) vectors, driving higher titers of functional viral particles based on the application of ProteoNic's 2G UNic™ premium vector technology.

Key Points: 
  • LEIDEN, the Netherlands, Sept. 19, 2023 /PRNewswire/ -- Necstgen, a non-profit CDMO and ProteoNic, a leading provider of premium vector technology and services for efficient production of biologics, announce the successful development of improved lentiviral (LV) vectors, driving higher titers of functional viral particles based on the application of ProteoNic's 2G UNic™ premium vector technology.
  • Both companies, located on the Leiden Bio Science Park, recognise the need to increase viral titres and optimise production processes.
  • We will continue our efforts aimed at improving AAV and LV vectors, catering to both transient production systems and stable viral producer cell lines".
  • ProteoNic will offer licensing and co-development opportunities, while NecstGen plans to apply the technology in its CDMO business.

NecstGen and ProteoNic report development of improved viral vectors through the application of premium 2G UNic™ technology

Retrieved on: 
Tuesday, September 19, 2023
Tissue, LV, Center for Cell and Gene Therapy, Gene, Leiden Bio Science Park, Proteon Therapeutics, AAV, CDMO, Patient, Cell, Vaccine

LEIDEN, the Netherlands, Sept. 19, 2023 /PRNewswire/ -- Necstgen, a non-profit CDMO and ProteoNic, a leading provider of premium vector technology and services for efficient production of biologics, announce the successful development of improved lentiviral (LV) vectors, driving higher titers of functional viral particles based on the application of ProteoNic's 2G UNic™ premium vector technology.

Key Points: 
  • LEIDEN, the Netherlands, Sept. 19, 2023 /PRNewswire/ -- Necstgen, a non-profit CDMO and ProteoNic, a leading provider of premium vector technology and services for efficient production of biologics, announce the successful development of improved lentiviral (LV) vectors, driving higher titers of functional viral particles based on the application of ProteoNic's 2G UNic™ premium vector technology.
  • Both companies, located on the Leiden Bio Science Park, recognise the need to increase viral titres and optimise production processes.
  • We will continue our efforts aimed at improving AAV and LV vectors, catering to both transient production systems and stable viral producer cell lines".
  • ProteoNic will offer licensing and co-development opportunities, while NecstGen plans to apply the technology in its CDMO business.

ProteoNic announces broadening of GigaGen's rights to 2G UNic™ Technology

Retrieved on: 
Tuesday, November 1, 2022
Efficiency, Unic, Technology, Infection, Immunodeficiency, Partnership, Proteon Therapeutics, Head, Vaccine, Grifols

Under the agreement, GigaGen gains non-exclusive, worldwide commercial rights for application of ProteoNic's technology platform to the development and manufacturing of its mono- and polyclonal antibody drug candidates.

Key Points: 
  • Under the agreement, GigaGen gains non-exclusive, worldwide commercial rights for application of ProteoNic's technology platform to the development and manufacturing of its mono- and polyclonal antibody drug candidates.
  • ProteoNic's protein expression technology, 2G UNic, improves recombinant protein production levels across a range of mammalian host cells, selection systems and protein targets.
  • ProteoNic is a privately held company with offices in Leiden, the Netherlands and in the Boston area, USA.
  • The company commercializes its proprietary 2G UNic technology through licensing and partnership arrangements.

ProteoNic announces broadening of GigaGen's rights to 2G UNic™ Technology

Retrieved on: 
Tuesday, November 1, 2022
Efficiency, Unic, Technology, Infection, Immunodeficiency, Partnership, Proteon Therapeutics, Head, Vaccine, Grifols

Under the agreement, GigaGen gains non-exclusive, worldwide commercial rights for application of ProteoNic's technology platform to the development and manufacturing of its mono- and polyclonal antibody drug candidates.

Key Points: 
  • Under the agreement, GigaGen gains non-exclusive, worldwide commercial rights for application of ProteoNic's technology platform to the development and manufacturing of its mono- and polyclonal antibody drug candidates.
  • ProteoNic's protein expression technology, 2G UNic, improves recombinant protein production levels across a range of mammalian host cells, selection systems and protein targets.
  • ProteoNic is a privately held company with offices in Leiden, the Netherlands and in the Boston area, USA.
  • The company commercializes its proprietary 2G UNic technology through licensing and partnership arrangements.

ProteoNic announces licensing of its premium 2G UNic™ Technology Platform for Production of Biologics to FyoniBio

Retrieved on: 
Tuesday, July 5, 2022
CEO, GEX, Unic, CHO, ISO9001, Immortalised cell line, Proteon Therapeutics, GMP, PK, GCLP, Partnership, Technology, Solution, RCB, Fine chemical

Under the agreement, FyoniBio gains worldwide, non-exclusive commercial rights for application of ProteoNic technology in its proprietary CHOnamite platform.

Key Points: 
  • Under the agreement, FyoniBio gains worldwide, non-exclusive commercial rights for application of ProteoNic technology in its proprietary CHOnamite platform.
  • ProteoNic's premium protein expression technology 2G UNic improves production levels across a range of mammalian cell types, selection systems and product classes.
  • The company offers technology and services for the generation of cell lines with greatly improved biologics production characteristics, including production levels and stability.
  • FyoniBio is part of the Canton Biologics group, a private-funded science-driven enterprise located in the Canton greater Bay area, China.

ProteoNic announces licensing of its premium 2G UNic™ Technology Platform for Production of Biologics to FyoniBio

Retrieved on: 
Tuesday, July 5, 2022
CEO, GEX, Unic, CHO, ISO9001, Immortalised cell line, Proteon Therapeutics, GMP, PK, GCLP, Partnership, Technology, Solution, RCB, Fine chemical

Under the agreement, FyoniBio gains worldwide, non-exclusive commercial rights for application of ProteoNic technology in its proprietary CHOnamite platform.

Key Points: 
  • Under the agreement, FyoniBio gains worldwide, non-exclusive commercial rights for application of ProteoNic technology in its proprietary CHOnamite platform.
  • ProteoNic's premium protein expression technology 2G UNic improves production levels across a range of mammalian cell types, selection systems and product classes.
  • The company offers technology and services for the generation of cell lines with greatly improved biologics production characteristics, including production levels and stability.
  • FyoniBio is part of the Canton Biologics group, a private-funded science-driven enterprise located in the Canton greater Bay area, China.

ProteoNic Announces Licensing of its 2G UNic™ Technology Platform for Production of Biologics to GenScript ProBio

Retrieved on: 
Wednesday, June 15, 2022
Partnership, CEO, Drug discovery, CGT, GenScript Biotech, Proteon Therapeutics, Efficiency, Drug development, Unic, CDMO, Technology, Immortalised cell line, Vaccine, Fine chemical, Pharmaceutical industry

LEIDEN, Netherlands, June 15, 2022 /PRNewswire/ -- ProteoNic BV, a leading provider of premium vector technology and services for efficient production of biologics, today announced licensing of its premium 2G UNic technology for boosting therapeutic protein production to GenScript ProBio, a global contract development and manufacturing organization.

Key Points: 
  • LEIDEN, Netherlands, June 15, 2022 /PRNewswire/ -- ProteoNic BV, a leading provider of premium vector technology and services for efficient production of biologics, today announced licensing of its premium 2G UNic technology for boosting therapeutic protein production to GenScript ProBio, a global contract development and manufacturing organization.
  • Under the agreement, GenScript ProBio gains access to ProteoNic technology for the development of high-yielding cell lines for its clients.
  • ProteoNic's premium protein expression technology 2G UNic improves production levels across a range of mammalian host cells, selection systems and protein targets.
  • Dr. Brian Min, CEO of GenScript ProBio commented: "GenScript ProBio has continuously developed and optimized cell line technology to improve the titer of challenging molecules.